This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read MaxCyte’s 8K filing here.
MaxCyte Company Profile
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
See Also
- Five stocks we like better than MaxCyte
- What Are the U.K. Market Holidays? How to Invest and Trade
- California Resources Stock Could Be a Huge Long-Term Winner
- 3 Tickers Leading a Meme Stock Revival
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- Insider Trading – What You Need to Know
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
